TD Ameritrade Investment Management’s Genmab GMAB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
Sell
-2,254
Closed -$86K 181
2023
Q2
$86K Sell
2,254
-127
-5% -$5.06K ﹤0.01% 225
2023
Q1
$90K Sell
2,381
-585
-20% -$22.5K ﹤0.01% 232
2022
Q4
$126K Sell
2,966
-877
-23% -$36.1K ﹤0.01% 221
2022
Q3
$123K Sell
3,843
-376
-9% -$13.2K ﹤0.01% 235
2022
Q2
$137K Sell
4,219
-678
-14% -$22K ﹤0.01% 242
2022
Q1
$177K Sell
4,897
-344
-7% -$11.8K ﹤0.01% 248
2021
Q4
$207K Buy
5,241
+2,173
+71% +$90.6K ﹤0.01% 239
2021
Q3
$112K Sell
3,068
-1,444
-32% -$64.8K ﹤0.01% 248
2021
Q2
$184K Buy
4,512
+895
+25% +$34.5K ﹤0.01% 244
2021
Q1
$147K Hold
3,617
﹤0.01% 239
2020
Q4
$147K Buy
3,617
+549
+18% +$20.5K ﹤0.01% 239
2020
Q3
$112K Buy
3,068
+324
+12% +$11.7K ﹤0.01% 248
2020
Q2
$93K Buy
2,744
+268
+11% +$7.3K ﹤0.01% 251
2020
Q1
$52K Sell
2,476
-10
-0.4% -$223 ﹤0.01% 288
2019
Q4
$56K Buy
2,486
+998
+67% +$21.8K ﹤0.01% 301
2019
Q3
$30K Buy
+1,488
New +$29.3K ﹤0.01% 347

Other funds holding GMAB

TD Ameritrade Investment Management's GMAB Position: Q3 2023 in Review

TD Ameritrade Investment Management sold out of Genmab (GMAB) in Q3 2023, closing a stake of 2,254 shares — an estimated $86K sold.

TD Ameritrade Investment Management first reported a position in GMAB in Q3 2019 and held it in 16 quarters. The position peaked at $207K in Q4 2021. 233 funds tracked by Wall St. Rank hold GMAB as of Q3 2023.

  • TD Ameritrade Investment Management reported no remaining Genmab position as of Q3 2023 after selling out during the quarter.
  • TD Ameritrade Investment Management sold 2,254 Genmab shares in Q3 2023, an estimated $86K.
  • TD Ameritrade Investment Management first reported a position in Genmab in Q3 2019 and held it in 16 quarters.
  • TD Ameritrade Investment Management's Genmab position peaked at $207K in Q4 2021.
  • 233 funds tracked by Wall St. Rank held Genmab as of Q3 2023.

Based on TD Ameritrade Investment Management's 13F filing for Q3 2023.